Calonge Margarita, Herreras José M
Ocular Immunology Clinical Unit and Ocular Surface Research Group, IOBA (Institute of Applied Ophthalmobiology), University of Valladolid, Valladolid, Spain.
Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):442-5. doi: 10.1097/ACI.0b013e3282efd0bf.
Atopic keratoconjunctivitis (AKC), the most severe and chronic form of ocular surface allergy-related disorder, is the ocular surface complication that some atopic dermatitis patients can suffer. Its wide range of severity, from mild and occasional problems to persistent and intense inflammation, makes it difficult to appropriately select uniform patients for clinical studies. This article proposes a new classification system for AKC based on clinical severity.
Recent reports on AKC have contributed to a better understanding of the pathogenesis and clinical manifestations, and are offering new therapeutic candidates for AKC. No reports, however, have been found that address a classification of this disease.
A new definition and classification for AKC is presented by this review, based on clinical severity, grading the main symptoms and signs. It intends to serve as a first forum of discussion among clinicians and other scientists working in the field of ocular surface inflammation. The final intention is to have a common language helping develop efficient clinical trials leading to successful approval of new therapeutic compounds for this blinding ocular surface condition.
特应性角结膜炎（AKC）是眼表过敏相关疾病中最严重和慢性的形式，是一些特应性皮炎患者可能出现的眼表并发症。其严重程度范围广泛，从轻微和偶尔的问题到持续和强烈的炎症，这使得难以适当选择统一的患者进行临床研究。本文基于临床严重程度提出了一种新的AKC分类系统。
最近关于AKC的报告有助于更好地理解其发病机制和临床表现，并为AKC提供了新的治疗候选药物。然而，尚未发现有报告涉及该疾病的分类。
本综述基于临床严重程度，对主要症状和体征进行分级，提出了AKC的新定义和分类。它旨在成为眼表炎症领域的临床医生和其他科学家之间的第一个讨论平台。最终目的是拥有一种通用语言，有助于开展高效的临床试验，从而成功批准用于这种致盲性眼表疾病的新治疗化合物。
